[Quality of registration of dementia diagnosis in primary care: The situation in Spain in 2002-2011].

Autor:	de Hoyos-Alonso Mdel C; Centro de Salud Pedro Laín Entralgo, DA Oeste, Servicio Madrileño de Salud, Alcorcón, Madrid, España. Electronic address: canto-hoyos@gmail.com., Bonis J; Programa BIFAP, División de Farmacoepidemiología y Farmacovigilancia, Agencia Española del Medicamento y Productos Sanitarios, Madrid, España., Bryant V; Programa BIFAP, División de Farmacoepidemiología y Farmacovigilancia, Agencia Española del Medicamento y Productos Sanitarios, Madrid, España., Castell Alcalá MV; Centro de Salud Dr. Castroviejo, DA Norte, Servicio Madrileño de Salud, Madrid, España; IdiPAZ, Instituto de Investigación La Paz, Madrid, España., Otero Puime Á; IdiPAZ, Instituto de Investigación La Paz, Madrid, España; Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid (UAM), Madrid, España.
Jazyk:	Spanish; Castilian
Zdroj:	Atencion primaria [Aten Primaria] 2016 Jan; Vol. 48 (1), pp. 33-41. Date of Electronic Publication: 2015 May 27.
DOI:	10.1016/j.aprim.2015.03.002
Abstrakt:	Objective: To ascertain the diagnosis associated with specific treatment for dementia in the Primary Care Electronic Clinical Record (PC-ECR) and to analyse the factors associated with the quality of registration. Methods: Descriptive study of patients taking cholinesterase inhibitors or memantine registered in Database for pharmacoepidemiological research in PC (BIFAP) 2011: 24,575 patients between 2002 and 2011. Diagnoses associated with first prescription of these drugs were grouped into 5 categories: "dementia", "memory impairment", "dementia-related diseases", "intercurrent processes" and "convenience codes". We calculated the prevalence of each category by age and sex for each study year (95%CI) and analysed the associations and trend for 2002-2011 using difference in proportions in independent samples and binary logistic regression. Results: A code of "dementia" was associated with first prescription in 56.5% (95%CI: 55.8-57.1) of patients. It was higher in women [OR1.09 (95%CI: 1.03-1.15)] and with increasing follow-up time [OR1.07 (95%CI: 1.06-1.08) for each year of follow-up]. "Convenience codes" [16.3% (95%CI: 15.8-16.7)] were coded more frequently in women and in those ≥80 years; "Memory impairment" [12.4% (95%CI: 12.0-12.8)], "related diseases" [4.6% (95%CI: 4.4-4.8)] and "intercurrent processes" [10.3% (95%CI: 9.9-10.6)] were used more in men and in persons <80 years. Between 2002 and 2011 improved the use of "convenience codes". Conclusions: Almost half of the patients taking cholinesterase inhibitors or memantine do not have a diagnosis of dementia registered in their PC-ECR. Registration improves with increasing time of follow-up. Improvements are needed in the PC-ECR, adequate care coordination, and proactive approach to increase the quality of dementia registration. (Copyright © 2014 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu